MUC16 and idiopathic pulmonary fibrosis: In conclusion, data from the INMARK trial suggest that in subjects with IPF and preserved FVC, nintedanib may have early and significant effects on circulating levels of CA-125 and, to a lesser extent, effects on SP-D, C3A and C3M.